BioAge Labs (NASDAQ:BIOA) Upgraded by Wall Street Zen to "Sell" Rating

Key Points

• Wall Street Zen upgraded BioAge Labs from “strong sell” to “sell,” while overall analyst sentiment remains “Moderate Buy,” with six Buy ratings and one Sell rating and a consensus price target of $36.57.
• BioAge shares opened at $8.49, down 1.8%, substantially below their 50-day and 200-day moving averages. The stock has traded between $4.68 and $25.95 over the past year.
• BioAge reported a quarterly loss of $0.58 per share, beating estimates for a $0.65 loss, but posted $2.45 million in revenue, a negative 912.26% net margin, and analysts expect a full-year loss of $2.45 per share.

BioAge Labs (NASDAQ:BIOA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Sunday, Wall Street Zen reports.

Several other equities analysts also recently weighed in on the company. Needham & Company LLC decreased their target price on BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $40.00 target price on shares of BioAge Labs in a research note on Tuesday, September 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioAge Labs in a report on Tuesday, July 21st. Roth Capital restated a "buy" rating and set a $25.00 target price on shares of BioAge Labs in a report on Wednesday. Finally, Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs has an average rating of "Moderate Buy" and a consensus target price of $36.57.

BioAge Labs Trading Down 1.8%

BIOA opened at $8.49 on Friday. The firm has a 50 day moving average of $14.93 and a two-hundred day moving average of $17.45. The firm has a market capitalization of $389.69 million, a PE ratio of -3.57 and a beta of 0.94. BioAge Labs has a 12-month low of $4.68 and a 12-month high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The company had revenue of $2.45 million during the quarter. As a group, analysts predict that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIOA. BlackRock Inc. acquired a new position in BioAge Labs in the second quarter valued at approximately $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs in the 2nd quarter valued at $52,597,000. Janus Henderson Group PLC raised its stake in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after acquiring an additional 1,685,063 shares in the last quarter. Octagon Capital Advisors LP lifted its position in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock valued at $30,573,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock worth $9,709,000 after purchasing an additional 93,694 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.